These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19562423)

  • 1. Implications of randomized studies of medical therapy vs revascularization for reducing rising costs of health care.
    Beller GA
    J Nucl Cardiol; 2009; 16(4):483-5. PubMed ID: 19562423
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
    Hlatky MA; Boothroyd DB; Melsop KA; Kennedy L; Rihal C; Rogers WJ; Venkitachalam L; Brooks MM;
    Circulation; 2009 Dec; 120(25):2550-8. PubMed ID: 19920002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous coronary intervention "dominates" coronary artery bypass graft surgery for high-risk patients: good news for patients, a challenge for healthcare planners.
    Radford MJ
    Circulation; 2006 Sep; 114(12):1229-31. PubMed ID: 16982950
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).
    Amin AP; Reynolds MR; Lei Y; Magnuson EA; Vilain K; Durtschi AJ; Simonton CA; Stone GW; Cohen DJ
    Am J Cardiol; 2012 Sep; 110(6):765-70. PubMed ID: 22651880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents: more dollars than sense?
    Garg S; Eisenberg MJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1188-9. PubMed ID: 20129544
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting.
    Birim Ö; Bogers AJ; Kappetein AP
    J Cardiovasc Surg (Torino); 2012 Oct; 53(5):641-50. PubMed ID: 22252542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.
    Bonaventura K; Leber AW; Sohns C; Roser M; Boldt LH; Kleber FX; Haverkamp W; Dorenkamp M
    Clin Res Cardiol; 2012 Jul; 101(7):573-84. PubMed ID: 22350752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients.
    Stroupe KT; Morrison DA; Hlatky MA; Barnett PG; Cao L; Lyttle C; Hynes DM; Henderson WG;
    Circulation; 2006 Sep; 114(12):1251-7. PubMed ID: 16966588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary revascularization in multivessel disease. Which is better, stents or surgery?
    Almeda FQ; Snell RJ
    Postgrad Med; 2005 Dec; 118(6):11-7. PubMed ID: 16382760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease.
    Hlatky MA; Melsop KA; Boothroyd DB;
    Am J Cardiol; 2006 Jun; 97(12A):59G-65G. PubMed ID: 16813739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of alternative approaches to the management of chronic obstructive coronary artery disease.
    Amin AP; Cohen DJ
    Rev Cardiovasc Med; 2009; 10 Suppl 2():S3-13. PubMed ID: 19898279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-generation drug-eluting stents and the continuous need for rapidly available real-world data.
    Mukherjee D; Moliterno DJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1236-9. PubMed ID: 20129550
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA.
    Rossetti F; De Portu S; Menditto E; Scalone L; Bustacchini S; Cricelli C; Mantovani LG
    Pharmacol Res; 2006 Mar; 53(3):197-201. PubMed ID: 16406672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the economic attractiveness of coronary artery revascularization in chronic kidney disease patients.
    Eisenstein EL; Sun JL; Anstrom KJ; DeLong ER; Szczech LA; Mark DB
    J Med Syst; 2009 Aug; 33(4):287-97. PubMed ID: 19697695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization analysis of three decision strategies for cardiac revascularization: results of the "suspected CAD" cohort of the european cardiovascular magnetic resonance registry.
    Moschetti K; Petersen SE; Pilz G; Kwong RY; Wasserfallen JB; Lombardi M; Korosoglou G; Van Rossum AC; Bruder O; Mahrholdt H; Schwitter J
    J Cardiovasc Magn Reson; 2016 Jan; 18():3. PubMed ID: 26754743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of coronary revascularisation.
    Birim O; Bogers AJ; Kappetein AP
    EuroIntervention; 2010 Feb; 5(7):763-7. PubMed ID: 20142188
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute and long-term cost implications of coronary stenting.
    Peterson ED; Cowper PA; DeLong ER; Zidar JP; Stack RS; Mark DB
    J Am Coll Cardiol; 1999 May; 33(6):1610-8. PubMed ID: 10334432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost estimates for treatment of cardiac ischemia (from the Asymptomatic Cardiac Ischemia Pilot [ACIP] study).
    Pepine CJ; Mark DB; Bourassa MG; Chaitman BR; Davies RF; Knatterud GL; Forman S; Pratt CM; Sopko G; Conti CR
    Am J Cardiol; 1999 Dec; 84(11):1311-6. PubMed ID: 10614796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.